Abstract
Background: Amifostine is a cytoprotective agent used to prevent cisplatin nephrotoxicity. It is associated with dose-limiting acute toxicities of emetic symptoms (nausea and vomiting) and transient hypotension.
Objective: The aim of this study was to analyze the efficacy and tolerability of amifostine in elderly cancer patients.
Methods: This 18-month, prospective, comparative study was conducted at the Department of Internal Medicine, Adnan Menderes University Hospital (Aydin, Turkey). Adult (aged 40−<85 years) hospitalized patients with advanced-stage cancer without comorbid diseases were enrolled. Patients were divided into 2 groups: age <70 years (group 1) and ≥70 years (group 2). All patients were treated with amifostine + cisplatin-based chemotherapy (CT). Amifostine 910 mg/m2 (maximum, 1500 mg) was administered as a 15-minute IV infusion. Clinical systolic and diastolic blood pressures (SBP and DBP, respectively) were measured at 0 minute (baseline), at 8 and 15 minutes of amifostine infusion, and at 30 minutes after the start of amifostine infusion. In addition to physical examination, chest radiography, electrocardiography, blood chemistry (including serum electrolytes and renal function tests), complete blood count, and complete urinalyses were performed before each CT administration and at the post-CT day of toxicity assessment.
Results: Thirty-five consecutive patients were enrolled (22 men, 13 women; mean [SD] age, 61 [12] years; group 1, n = 22; group 2, n = 13). Patients received a total of 153 CT cycles (median, 4 cycles/patient; group 1, 96 cycles; group 2, 57 cycles). Amifostine caused significant SBP and DBP reductions at 8 minutes of infusion compared with baseline in groups 1 (both P < 0.001) and 2 (P = 0.002 and P = 0.006, respectively). Overall, 20 patients (57.1%) experienced ≥ 1 symptomatic hypotensive episode; these rates were not significantly different between groups 1 (11 cases, 50.0%) and 2 (9 cases, 69.2%). Amifostine infusion was interrupted a similar number of times (6 times in group 1 and 4 times in group 2 [6.3% and 7.0% of administrations, respectively]) due to hypotension, but could be restarted in all. At 15 minutes, mean SBP and DBP values were not significantly different from baseline in either group. The mean baseline SBP values were similar between groups at baseline, and, overall, the differences in mean SBP and DBP values were not significant between groups at any time point. All other toxicities were comparable, and serum creatinine concentrations did not change significantly from baseline with CT in either group.
Conclusions: In this study of the efficacy and tolerability of amifostine in elderly patients with advanced-stage cancer without comorbid diseases, amifostine was effective in reducing cisplatin-induced nephrotoxicity, with transient systolic and diastolic hypotension being the most prominent adverse effect. All other toxicities were either low grade or preventable. No significant differences in amifostine tolerability or toxicities were observed between the study groups.
Keywords: amifostine, adverse effects, elderly cancer patients, tolerability, cisplatin, nephrotoxicity
Full Text
The Full Text of this article is available as a PDF (672.4 KB).
References
- 1.Sriswasdi C, Jootar S, Giles F.J. Amifostine and hematologic effects. J Med Assoc Thai. 2000;83:374–382. [PubMed] [Google Scholar]
- 2.Genvresse I, Lange C, Schanz J. Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: A comparative study. Anticancer Drugs. 2001;12:345–349. doi: 10.1097/00001813-200104000-00007. [DOI] [PubMed] [Google Scholar]
- 3.Mabro M, Faivre S, Raymond E. A risk-benefit assessment of amifostine in cytoprotection. Drug Saf. 1999;21:367–387. doi: 10.2165/00002018-199921050-00003. [DOI] [PubMed] [Google Scholar]
- 4.Antonadou D, Coliarakis N, Synodinou M, Clinical Radiation Oncology Hellenic Group Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 2002;52:1458. doi: 10.1016/s0360-3016(01)01713-8. published correction appears in. [DOI] [PubMed] [Google Scholar]; Antonadou D, Coliarakis N, Synodinou M, Clinical Radiation Oncology Hellenic Group Int J Radiat Oncol Biol Phys. 2002;54:308. doi: 10.1016/s0360-3016(01)01713-8. [DOI] [PubMed] [Google Scholar]; Antonadou D, Coliarakis N, Synodinou M, Clinical Radiation Oncology Hellenic Group Int J Radiat Oncol Biol Phys. 2001;51:915–922. doi: 10.1016/s0360-3016(01)01713-8. [DOI] [PubMed] [Google Scholar]
- 5.Buntzel J, Kuttnerz K, Frohlich D, Glatzel M. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol. 1998;9:505–509. doi: 10.1023/a:1008282412670. [DOI] [PubMed] [Google Scholar]
- 6.Brizel D.M, Wasserman T.H, Henke M. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000;18:4110–4111. doi: 10.1200/JCO.2000.18.19.3339. published correction appears in. [DOI] [PubMed] [Google Scholar]; Brizel D.M, Wasserman T.H, Henke M. J Clin Oncol. 2000;18:3339–3345. doi: 10.1200/JCO.2000.18.19.3339. [DOI] [PubMed] [Google Scholar]
- 7.Vacha P, Fehlauer F, Mahlmann B. Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol. 2003;179:385–389. doi: 10.1007/s00066-003-1016-1. [DOI] [PubMed] [Google Scholar]
- 8.Lorusso D, Ferrandina G, Greggi S, Multicenter Italian Trials in Ovarian Cancer Investigators Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol. 2003;14:1086–1093. doi: 10.1093/annonc/mdg301. [DOI] [PubMed] [Google Scholar]
- 9.Kemp G, Rose P, Lurain J. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: Results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996;14:2101–2112. doi: 10.1200/JCO.1996.14.7.2101. [DOI] [PubMed] [Google Scholar]
- 10.Cui H, Zhang S, Li P. Amifostine in protection of kidney from cisplatinum injury. Zhonghua Zhong Liu Za Zhi. 2002;24:48–50. [in Chinese] [PubMed] [Google Scholar]
- 11.Hensley M.L, Schuchter L.M, Lindley C. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333–3355. doi: 10.1200/JCO.1999.17.10.3333. [DOI] [PubMed] [Google Scholar]
- 12.Orditura M, De Vita F, Roscigno A. Amifostine: A selective cytoprotective agent of normal tissues from chemo-radiotherapy induced toxicity. Oncol Rep. 1999;6:1357–1362. doi: 10.3892/or.6.6.1357. [DOI] [PubMed] [Google Scholar]
- 13.Komaki R, Lee J.S, Kaplan B. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II–III non-small cell lung cancer: Preliminary results. Semin Radiat Oncol. 2002;12(Suppl 1):46–49. doi: 10.1053/srao.2002.31363. [DOI] [PubMed] [Google Scholar]
- 14.Aapro M, Extermann M, Repetto L. Evaluation of the elderly with cancer. Ann Oncol. 2000;11(Suppl 3):223–229. doi: 10.1093/annonc/11.suppl_3.223. [DOI] [PubMed] [Google Scholar]
- 15.Oken M.M, Creech R.H, Tormey D.C. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649–655. [PubMed] [Google Scholar]
- 16.Tamhane A.C, Logan B.R. Accurate critical constants for the one-sided approximate likelihood ratio test of a normal mean vector when the covariance matrix is estimated. Biometrics. 2002;58:650–656. doi: 10.1111/j.0006-341x.2002.00650.x. [DOI] [PubMed] [Google Scholar]
- 17.Bukowski R.M. Amifostine (Ethyol): Dosing, administration and patient management guidelines. Eur J Cancer. 1996;32A(Suppl 4):S46–S49. doi: 10.1016/s0959-8049(96)00328-0. [DOI] [PubMed] [Google Scholar]
- 18.Blumberg A.L, Nelson D.F, Gramkowski M. Clinical trials of WR-2721 with radiation therapy. Int J Radiat Oncol Biol Phys. 1982;8:561–563. doi: 10.1016/0360-3016(82)90684-8. [DOI] [PubMed] [Google Scholar]
- 19.Viele C.S, Holmes B.C. Amifostine: Drug profile and nursing implications of the first pancytoprotectant. Oncol Nurs Forum. 1998;25:515–523. [PubMed] [Google Scholar]
- 20.Koukourakis M.I. Amifostine in clinical oncology: Current use and future applications. Anticancer Drugs. 2002;13:181–209. doi: 10.1097/00001813-200203000-00001. [DOI] [PubMed] [Google Scholar]
- 21.Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Saf. 2001;24:19–38. doi: 10.2165/00002018-200124010-00003. [DOI] [PubMed] [Google Scholar]
- 22.Dorr R.T, Holmes B.C. Dosing considerations with amifostine: A review of the literature and clinical experience. Semin Oncol. 1999;26(Suppl 7):108–119. [PubMed] [Google Scholar]
- 23.Anne P.R. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer. Semin Oncol. 2003;30:417. doi: 10.1053/sonc.2002.37350b. published correction appears in. [DOI] [PubMed] [Google Scholar]; Anne P.R. Semin Oncol. 2002;29(Suppl 19):80–83. doi: 10.1053/sonc.2002.37350b. [DOI] [PubMed] [Google Scholar]
- 24.Bardet E, Martin L, Calais G. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol. 2002;29(Suppl 19):57–60. doi: 10.1053/sonc.2002.37348. [DOI] [PubMed] [Google Scholar]
- 25.Ryan S.V, Carrithers S.L, Parkinson S.J. Hypotensive mechanisms of amifostine. J Clin Pharmacol. 1996;36:365–373. doi: 10.1002/j.1552-4604.1996.tb04214.x. [DOI] [PubMed] [Google Scholar]
- 26.Gridelli C, Cigolari S, Maiorino A. Amifostine plus cisplatin plus vinorelbine in the treatment of advanced non small cell lung cancer: A multicenter phase II study. Lung Cancer. 2000;28:237–244. doi: 10.1016/s0169-5002(99)00131-2. [DOI] [PubMed] [Google Scholar]